Selected References
- Agache I, et al. 2020. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. May;75(5):1023-1042
- Fasenra® Prescribing Information. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf. Accessed on Feb 2nd, 2021.
- LactMed. 2020. Benralizumab. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-2020 Jul 20. PMID: 30000011. Bookshelf ID: NBK500952
- Manetz S, et al. 2020. Successful pregnancy in setting of eosinophil depletion by benralizumab. J Allergy Clin Immunol Pract. Dec 13;S2213-2198(20)31335-0. doi: 10.1016/j.jaip.2020.11.060. Online ahead of print.
- Middleton PG, et al. 2020. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. Feb 6;55:1901208. doi: 10.1183/13993003.01208-2019.
